~~<i id='C7B1F7AB17'><strike id='C7B1F7AB17'><tt id='C7B1F7AB17'><pre id='C7B1F7AB17'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：focus 2025-09-27 20:35:29 Page View：16

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ASCO: AstraZeneca says CAR
Next article： Guidelines to prevent youth baseball injuries need more muscle

focus

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Amylyx ALS drug fails large clinical trial

JustinKlee(left)andJoshuaCohenaretheco-foundersandco-CEOsofAmylyxPharmaceuticals.KayanaSzymczakforST

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ANDREWYATES/AFPviaGettyImagesInpatientswithstage3lungcancerwhereaparticulargeneticmutationispresenti

WSS

knowledge

knowledge

explore

focus

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers